Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It’s better to get the data from different corners of the world.
Not many Aim companies that have Fda approval for medical research either.
Doc - It wasn’t aimed at anyone in particular.
We all would have loved things to move a bit quicker but when you step back and look at similar sized biotechs we really are punching.
The majors can get away with cutting a few corners, companies without proven track records have to jump through all the hoops I’m afraid.
Still thousands of cases in UK and our trial started a while bk already.. no way we will have issues filling up the trial.. US will keep having thousands of cases a day until mid May for sure... ppl freaking out about this shouldn’t be invested here, just means they know very little and have done little research..
People need to relax a bit here if there’s one thing SNG know how to do it is how to punch above their weight and get top quality trial data banked.
If you have followed the covid therapeutic story since last year you will be well aware of all the companies that raised cash to run trials for covid many of them on aim.
The list of AIM companies that succeeded in completing the first trial is very short, the list of companies that went onto complete a second trial is SNG and the list of companies that went on to bank a further P2 and P3 trials is again just SNG.
They seem to know what they are doing let’s leave them too it and support them by holding onto your shares.
Doc
Thanks for your opinion which I respect and value .Between everything it may be I have been more interested in the evidence for the science and not all the twists and turns in regulatory processes and various trials etc If what you say is correct it will test my patience little more ,but I am always optimistic that something good and unexpected might materialize sooner .Here's Hoping
ATB
I agree with Harchris and from my recollections a read out will be based on some threshold number, say 200 of the 610 across all global sites It is a matter of expedience that data is released so decisions can be made for approval .I stand to be corrected if anybody disagrees . Waiting another month or more seems to the antithesis of what was intended to obtain quickly a data set to trigger emergency approval
Re your first question - I really don’t know. Was just playing it safe by assuming it’ll be based on a global number.
Note, I was just making a hypothetical statement to say that should they plan to make an interim analysis I hope we reach that magic number soon to enable such an analysis.
I think the US has already started & I think there are more sites than just Texas. I wouldn’t go based on the protocol as an indication of whether recruitment has started or not. Europe has already started. Remember there are two months left to finish recruitment if they were to meet their own set primary completion date so they must be close to or around half way by now (at least).
The article someone posted the other day re the trials in the Serbian hospitals said they had already recruited 40 patients in the uk arm. It was published on 2 Feb, I think 20 days after the first patient was dosed. So roughly recruiting 2 a day (just over hopefully). So by now - moving on >30 days they hopefully have at least 100 in the UK arm and have ramped up trials in other countries in case UK recruitment is slowing.
So to get this straight, an interim readout will not happen based on the UK arm alone, it will be based on some threshold number, say 200 of the 610 across all global sites? It appears to me the UK is the only nation with patients so far, with the US to come online very soon (Texas was named the other day). If that's the case we would be looking at something like 120 UK enrolled and 80 international, for an interim readout?
It all depends on how many they aim to recruit in the UK. I’m confident, or rather hope, the original target of 200 would’ve been reduced accordingly (to let’s say between 100 - 135) so based on that assumption I’d say end of March would be a reasonable guesstimate. But, I/we just don’t know.
According to the protocol the 610th patient should be enrolled on 04 May at the latest to meet the primary completion date.
What’s more important I think is how quickly and when we can reach the magic number across all global sites to warrant an interim analysis should they do one.
Matterhorn do you reckon the UK arm will be filled before March is out? My guess is more like end of April but it's not based on any hard facts (don't think any of us have those to hand right now).
Since 26 Feb, except for one day, fewer covid 19 patients were admitted to hospital per day in England than at the same point, give or take a day, during the first wave. I’m using the peak in admissions as a reference point which is also when both SG016 & SG018 started. On average 55 patients fewer per day from 26 Feb.
Hopefully we don't have that many more to recruit into SG018 in England.